View of A Prospective Randomised Open Label Study to Evaluate the Response Rate and Toxicity of Gefitinib in the Treatment of Carcinoma Cervix Patients on Chemoradiotherapy

Return to Article Details A Prospective Randomised Open Label Study to Evaluate the Response Rate and Toxicity of Gefitinib in the Treatment of Carcinoma Cervix Patients on Chemoradiotherapy Download Download PDF